Urokinase
Protein / enzyme biologic targets PLAU
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | KINLYTIC | — | 1981-04-20 – 1983-10-14 | fda.gov ↗ |
| Approved | US (FDA) | KINLYTIC | — | 1978-01-16 | fda.gov ↗ |
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00144950 | — | empyema | Institute of Child Health | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01108120 | May 2010 → Dec 2022 | ulcer of lower limbs | Xiang Guang-da | Completed | No outcome recorded |
| Phase 2 | NCT00537498 | Feb 2002 → Dec 2006 | arterial occlusion, limb ischemia | medac GmbH | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01204333 | Sep 2011 → Dec 2016 | intracranial sinus thrombosis | Jan Stam, MD, PhD | Terminated | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT04420351 | Oct 2020 → Feb 2023 | stroke disorder | The First Affiliated Hospital of Zhengzhou University | Completed | No outcome recorded |
| Phase 3 | NCT02036255 | May 2015 → Jul 2017 | infectious disease | University Hospital Brussels | Completed | No outcome recorded |
| Phase 3 | NCT02165891 | Feb 2015 → Jun 2020 | pleural empyema | Queen Fabiola Children's University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00798278 | Jul 2008 → Sep 2010 | empyema, pneumonia | Spanish Society of Pediatric Surgery | Completed | No outcome recorded |
| Phase 3 | NCT00823225 | Jun 2008 → Jun 2009 | arterial occlusion, limb ischemia | medac GmbH | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02868697 | Nov 2013 → Aug 2015 | — | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00799968 | Jun 2002 → Feb 2006 | pulmonary embolism, venous thromboembolism | Beijing Chao Yang Hospital | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07047326 | Oct 2025 → Oct 2026 expected | ischemic stroke | Capital Medical University | Recruiting | No outcome recorded |
| — | NCT06583889 | Aug 2024 → Jan 2029 expected | cerebral sinovenous thrombosis | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT03716375 | Nov 2018 → Apr 2019 | pleural empyema | Beijing Children's Hospital | Unknown | No outcome recorded |
| — | NCT02414802 | Dec 2014 → Dec 2017 | venous thromboembolism | Xuzhou Medical University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 11 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04516993 Background | Sep 2021 → Sep 2023 | stroke disorder | Huashan Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01222117 Comparator | Dec 2010 → Dec 2015 | peripheral arterial occlusive disease 1 | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00502632 Background | Oct 2007 → Oct 2009 | pleural empyema | Azienda Ospedaliera di Padova | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01638585 Comparator | Jun 2011 → Nov 2012 | limb ischemia | GWT-TUD GmbH | Terminated | No outcome recorded |
| Phase 3 | NCT01134237 Comparator | May 2010 → Aug 2013 | pleural disorder | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT06284642 Comparator | Mar 2024 → Jun 2027 expected | acquired aneurysmal subarachnoid hemorrhage | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 4 | NCT06802679 Comparator | Oct 2020 → Jan 2025 | end stage renal failure | National Healthcare Group, Singapore | Completed | No outcome recorded |
| Phase 4 | NCT01568931 Comparator | Jan 2014 → Mar 2020 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT00968929 Comparator | Jun 2006 → May 2009 | pulmonary embolism | Beijing Chao Yang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01246453 Comparator | Dec 2003 → Dec 2010 | pleural empyema | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06833827 Comparator | Feb 2025 → Jan 2028 expected | pulmonary embolism | Leiden University Medical Center | Recruiting | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | urokinase | “Standard reperfusion treatment for high-risk PE patients is thrombolytic therapy, typically consisting of Alteplase, Urokinase, or Tenecteplase, with the idea of accelerated...” NCT06833827 ↗25“Standard endovascular techniques to mechanically remove clot material, such as mechanical thrombectomy and/or balloon angioplasty and/or local application of alteplase or...” NCT06583889 ↗ “The aim of this study is to evaluate difference among intrapleural urokinase as the initial treatment for children with pleural empyema against chest tube drainage alone.” NCT03716375 ↗ “Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses.” NCT01204333 ↗ “taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000” NCT02868697 ↗ “continuous injection of urokinase via femoral artery by a artery mini-pump” NCT01108120 ↗ “urokinase (UK)” NCT01222117 ↗ |
| Known as | Abbokinase | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201420 ↗ |
| Known as | Kinase (enzyme-activating), uro- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201420 ↗ |
| Known as | Kinlytic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201420 ↗ |
| Known as | Ukidan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201420 ↗ |
| Known as | Urinary plasminogen activator | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201420 ↗ |
| Known as | urokinase (UK) | “urokinase (UK)” NCT01222117 ↗ |
| Known as | Uroquinasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201420 ↗ |
| Action | Activate | “Urokinase is a kind of non-selective plasminogen activator” NCT04420351 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1201420 ↗ |
| Route | Other | “urokinase instillation” NCT00144950 ↗ |
| Target | PLAU | “Urokinase-type plasminogen activator exogenous protein” CHEMBL1201420 ↗ |